Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide + neostigmine vs atropine + neostigmine for prevention of neostigmine‑induced bradycardia
CTR20231938Phase 3Completed
- Sponsor
- Ruiyang Pharmaceutical
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of neostigmine + glycopyrrolate in neuromuscular block (NMB), bradyarrhythmia, sponsored by Ruiyang Pharmaceutical. Started Jul 2023; status: completed.
02
Drugs
neostigmine + glycopyrrolate
03
Conditions
neuromuscular block (NMB)bradyarrhythmia
Beyond the preview
Go deeper on CTR20231938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231938.